Recent patents on calcium channel blockers: Emphasis on CNS diseases

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 9, 2014, Pages 959-977

  Arranz Tagarro, Juan Alberto ^a,b,c   De Los Ríos, Cristóbal ^a,c   García, Antonio G ^a,b,c   Padín, Juan Fernando ^a,b,c  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Calcium channel blockers; Epilepsy; Neurodegenerative diseases; Pain; Voltage activated calcium channels

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL T TYPE; CALCIUM; CALCIUM CHANNEL; LIGAND;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; EPILEPSY; HUMAN; IC 50; IN VITRO STUDY; MIGRAINE; MOLECULAR BIOLOGY; NONHUMAN; PAIN; PATENT; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; NEURONS; PATENTS AS TOPIC; SYNAPTIC TRANSMISSION;

EID: 84906219715     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.940892     Document Type: Review

References (148)

1. Ringer S. A further contribution regarding the influence of the. different constituents of the blood on the contraction of the heart. J Physiol 1883;4:29-42
2. Ringer S. Further experiments regarding the influence of small quantities of lime potassium and other salts on muscular tissue. J Physiol 1886;7:291-308
3. Locke F. Notiz über den einfluss, physiologischer kochsalzl̈osung auf die erregbarkeit von muscel und nerve. Zentralbl Physiol 1894;8:166-7
4. Overton E. Beiträge zur allgemeinen muskel-und nerven physiologie III. Mittheilung. Studien uber die wirkung der alkali-und erdkali-salze auf skeletalmuskeln und nerven. Pflugers Arch 1904;105:176-290
5. Heilbrunn LV, Wiercinski FJ. The action of various cations on muscle protoplasm. J Cell Physiol 1947;29:15-32
6. Katz B, Miledi R. The timing of calcium action during neuromuscular transmission. J Physiol 1967;189:535-44
7. Garcia AG, Garcia-De-Diego AM, Gandia L, et al. Calcium signaling and exocytosis in adrenal chromaffin cells. Physiol Rev 2006;86:1093-131
8. Garcia AG, Padin F, Fernandez-Morales JC, et al. Cytosolic organelles shape calcium signals and exo-endocytotic responses of chromaffin cells. Cell Calcium 2012;51:309-20
9. Garcia-Sancho J, de Diego AM, Garcia AG. Mitochondria and chromaffin cell function. Pflugers Arch 2012;464:33-41
10. Catterall WA, Leal K, Nanou E. Calcium channels and short-term synaptic plasticity. J Biol Chem 2013;288:10742-9
11. Fernandez-Morales JC, Arranz-Tagarro JA, Calvo-Gallardo E, et al. Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for alzheimer's disease. ACS Chem Neurosci 2012;3:873-83
12. Yu JT, Chang RC, Tan L. Calcium dysregulation in alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 2009;89:240-55
13. Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and parkinson's disease. Trends Neurosci 2009;32:249-56
14. Grosskreutz J, Van Den Bosch L, Keller BU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 2010;47:165-74
15. Berridge MJ. Calcium regulation of neural rhythms, memory and alzheimer's disease. J Physiol 2014;592(Pt 2):281-93
16. Carafoli E. Calcium signaling: a tale for all seasons. Proc Natl Acad Sci USA 2002;99:1115-22
17. MacDonald JF, Xiong ZG, Jackson MF. Paradox of ca2+ signaling, cell death and stroke. Trends Neurosci 2006;29:75-81
18. Triggle DJ. Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol 2007;74:1-9
19. de Diego AM, Lorrio S, Hernandez-Guijo JM, et al. Multitarget drugs for stabilization of calcium cycling and neuroprotection in neurodegenerative diseases and stroke. In: Botana LM, Loza MI, editors, Therapeutic targets: modulation, inhibition, and activation. John Wiley & Soons, Inc., Hoboken NJ, USA; 2012. p. 123-97
20. Fatt P, Ginsborg BL. The ionic requirements for the production of action potentials in crustacean muscle fibres. J Physiol 1958;142:516-43
21. Dolphin AC. A short history of voltagegated calcium channels. Br J Pharmacol 2006;147(Suppl 1):S56-62
22. Fleckenstein A. History of calcium antagonists. Circ Res 1983;52:I3-16
23. Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 2011;3:a003947
24. De Diego AM, Gandía L, Padín F, et al. Calcium channels for exocytosis and endocytosis: Pharmacological modulation. In: Botana LM, editor, Seafood and freshwater toxins: Pharmacology, physiology, and detection. Taylor & Francis Group, USA; 2014. p. 1215
25. Pragnell M, De Waard M, Mori Y, et al. Calcium channel beta-subunit binds to a conserved motif in the i-ii cytoplasmic linker of the alpha 1-subunit. Nature 1994;368:67-70
26. Van Petegem F, Clark KA, Chatelain FC, et al. Structure of a complex between a voltage-gated calcium channel beta-subunit and an alphasubunit domain. Nature 2004;429:671-5
27. Berggren PO, Yang SN, Murakami M, et al. Removal of ca2+ channel beta3 subunit enhances ca2+ oscillation frequency and insulin exocytosis. Cell 2004;119:273-84
28. Kang MG, Campbell KP. Gamma subunit of voltage-activated calcium channels. J Biol Chem 2003;278:21315-18
29. Chen L, Chetkovich DM, Petralia RS, et al. Stargazin regulates synaptic targeting of ampa receptors by two distinct mechanisms. Nature 2000;408:936-43
30. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000;25:533-5
31. Doering CJ, Zamponi GW. Molecular pharmacology of high voltage-activated calcium channels. J Bioenerg Biomembr 2003;35:491-505
32. Lipkind GM, Fozzard HA. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the l-type ca2+ channel. Mol Pharmacol 2003;63:499-511
33. Hockerman GH, Peterson BZ, Sharp E, et al. Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-l-type ca2+ channel. Proc Natl Acad Sci USA 1997;94:14906-11
34. Hockerman GH, Dilmac N, Scheuer T, et al. Molecular determinants of diltiazem block in domains iiis6 and ivs6 of l-type ca(2+) channels. Mol Pharmacol 2000;58:1264-70
35. Boland LM, Morrill JA, Bean BP. Omega-conotoxin block of n-type calcium channels in frog and rat sympathetic neurons. J Neurosci 1994;14:5011-27
36. Hillyard DR, Monje VD, Mintz IM, et al. A new conus peptide ligand for mammalian presynaptic ca2+ channels. Neuron 1992;9:69-77
37. Gandia L, Lara B, Imperial JS, et al. Analogies and differences between omega-conotoxins mviic and mviid: binding sites and functions in bovine chromaffin cells. Pflugers Arch 1997;435:55-64
38. Bourinet E, Stotz SC, Spaetgens RL, et al. Interaction of snx482 with domains iii and iv inhibits activation gating of alpha(1e) (ca(v)2.3) calcium channels. Biophys J 2001;81:79-88
39. Carbone E, Calorio C, Vandael DH. T-type channel-mediated neurotransmitter release. Pflugers Arch 2014;466:677-87
40. Chuang RS, Jaffe H, Cribbs L, et al. Inhibition of t-type voltage-gated calcium channels by a new scorpion toxin. Nat Neurosci 1998;1:668-74
41. Jarvis MF, Scott VE, McGaraughty S, et al. A peripherally acting, selective ttype calcium channel blocker, abt-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol 2014;89:536-44
42. Watanuki S, Matsuura K, Tomura Y, et al. Synthesis and pharmacological evaluation of 2-(1-alkylpiperidin-4-yl)-n-[(1r)-1-(4-fluorophenyl)-2- methylpropyl] acetamide derivatives as novel antihypertensive agents. Chem Pharm Bull (Tokyo) 2012;60:223-34
43. Garcez-Do-Carmo L, Albillos A, Artalejo AR, et al. R56865 inhibits catecholamine release from bovine chromaffin cells by blocking calcium channels. Br J Pharmacol 1993;110:1149-55
44. Villarroya M, Gandia L, Lara B, et al. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells. Br J Pharmacol 1995;114:369-76
45. Hernandez-Guijo JM, Gandia L, de Pascual R, et al. Differential effects of the neuroprotectant lubeluzole on bovine and mouse chromaffin cell calcium channel subtypes. Br J Pharmacol 1997;122:275-85
46. Grantham CJ, Main MJ, Cannell MB. Fluspirilene block of n-type calcium current in ngf-differentiated pc12 cells. Br J Pharmacol 1994;111:483-8
47. Enyeart JJ, Biagi BA, Mlinar B. Preferential block of t-type calcium channels by neuroleptics in neural crestderived rat and human c cell lines. Mol Pharmacol 1992;42:364-72
48. Valentino K, Newcomb R, Gadbois T, et al. A selective n-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993;90:7894-7
49. Qian J, Noebels JL. Presynaptic ca2+ channels and neurotransmitter release at the terminal of a mouse cortical neuron. J Neurosci 2001;21:3721-8
50. Zamponi GW, Lory P, Perez-Reyes E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch 2010;460:395-403
51. Vohora D, Saraogi P, Yazdani MA, et al. Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc) 2010;46:265-77
52. Suman-Chauhan N, Webdale L, Hill DR, et al. Characterisation of [3h] gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993;244:293-301
53. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76
54. Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at p/q-type voltagesensitive calcium channels: inhibition of k+-evoked [3h]-norepinephrine release from rat neocortical slices. Synapse 2002;45:171-90
55. Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20:1566-76
56. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of p/q-type ca2+ channels. Neuropharmacology 2004;46:743-9
57. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8
58. Lee CY, Chen CC, Liou HH. Levetiracetam inhibits glutamate transmission through presynaptic p/qtype calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 2009;158:1753-62
59. Pisani A, Bonsi P, Martella G, et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004;45:719-28
60. Stefani A, Spadoni F, Siniscalchi A, et al. Lamotrigine inhibits ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996;307:113-16
61. Zhu G, Okada M, Murakami T, et al. Interaction between carbamazepine, zonisamide and voltage-sensitive ca2+ channel on acetylcholine release in rat frontal cortex. Epilepsy Res 2002;49:49-60
62. Kostyuk PG, Molokanova EA, Pronchuk NF, et al. Different action of ethosuximide on low-and high-threshold calcium currents in rat sensory neurons. Neuroscience 1992;51:755-8
63. McGivern JG. Targeting n-type and ttype calcium channels for the treatment of pain. Drug Discov Today 2006;11:245-53
64. Santicioli P, Del Bianco E, Tramontana M, et al. Release of calcitonin gene-related peptide likeimmunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci Lett 1992;136:161-4
65. Smith MT, Cabot PJ, Ross FB, et al. The novel n-type calcium channel blocker, am336, produces potent dosedependent antinociception after intrathecal dosing in rats and inhibits substance p release in rat spinal cord slices. Pain 2002;96:119-27
66. Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new ntype calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000;25:274-8
67. Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anesth Perioper Med Pain 2000;19:67-75
68. Carbone E, Lux HD. A low voltageactivated, fully inactivating ca channel in vertebrate sensory neurones. Nature 1984;310:501-2
69. McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 2004;3:457-78
70. Francois A, Laffray S, Pizzoccaro A, et al. T-type calcium channels in chronic pain: mouse models and specific blockers. Pflugers Arch 2014;466:707-17
71. Todorovic SM, Jevtovic-Todorovic V. Targeting of cav3.2 t-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy. Pflugers Arch 2014;466:701-6
72. Kim D, Park D, Choi S, et al. Thalamic control of visceral nociception mediated by t-type ca2+ channels. Science 2003;302:117-19
73. Hall KE, Sima AA, Wiley JW. Voltage-dependent calcium currents are enhanced in dorsal root ganglion neurones from the bio bred/worchester diabetic rat. J Physiol 1995;486(Pt 2):313-22
74. Jagodic MM, Pathirathna S, Nelson MT, et al. Cell-specific alterations of t-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 2007;27:3305-16
75. Khomula EV, Viatchenko-Karpinski VY, Borisyuk AL, et al. Specific functioning of cav3.2 t-type calcium and trpv1 channels under different types of stz-diabetic neuropathy. Biochim Biophys Acta 2013;1832:636-49
76. Jacus MO, Uebele VN, Renger JJ, et al. Presynaptic cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci 2012;32:9374-82
77. Choe W, Messinger RB, Leach E, et al. Tta-p2 is a potent and selective blocker of t-type calcium channels in rat sensory neurons and a novel antinociceptive agent. Mol Pharmacol 2011;80:900-10
78. Hildebrand ME, Smith PL, Bladen C, et al. A novel slow-inactivation- specific ion channel modulator attenuates neuropathic pain. Pain 2011;152:833-43
79. Delfini MC, Mantilleri A, Gaillard S, et al. Tafa4, a chemokine-like protein, modulates injury-induced mechanical and chemical pain hypersensitivity in mice. Cell Rep 2013;5:378-88
80. Coulter DA, Huguenard JR, Prince DA. Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol 1990;100:800-6
81. Dogrul A, Gardell LR, Ossipov MH, et al. Reversal of experimental neuropathic pain by t-type calcium channel blockers. Pain 2003;105:159-68
82. Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunitsstructure and gabapentin binding. Mol Pharmacol 2001;59:1243-8
83. Sarantopoulos C, McCallum B, Kwok WM, et al. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg Anesth Pain Med 2002;27:47-57
84. Horga de la Parte JF, Horga A. [pregabalin: new therapeutic contributions of calcium channel alpha2delta protein ligands on epilepsy and neuropathic pain]. Rev Neurol 2006;42:223-37
85. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000;151:145-8
86. Hoffmann U, Dilekoz E, Kudo C, et al. Gabapentin suppresses cortical spreading depression susceptibility. J Cereb Blood Flow Metab 2010;30:1588-92
87. Rosa JM, Nanclares C, Orozco A, et al. Regulation by l-type calcium channels of endocytosis: an overview. J Mol Neurosci 2012;48:360-7
88. Comunanza V, Marcantoni A, Vandael DH, et al. Cav1.3 as pacemaker channels in adrenal chromaffin cells: specific role on exo-and endocytosis? Channels (Austin) 2010;4:440-6
89. Mangoni ME, Couette B, Bourinet E, et al. Functional role of l-type cav1.3 ca2 + channels in cardiac pacemaker activity. Proc Natl Acad Sci USA 2003;100:5543-8
90. Marcotti W, Johnson SL, Rusch A, et al. Sodium and calcium currents shape action potentials in immature mouse inner hair cells. J Physiol 2003;552:743-61
91. Olson PA, Tkatch T, Hernandez-Lopez S, et al. G-protein-coupled receptor modulation of striatal cav1.3 l-type ca2+ channels is dependent on a shank-binding domain. J Neurosci 2005;25:1050-62
92. Goswami C, Islam MS. Transient receptor potential channels: what's happening? Reflections in the wake of the 2009 trp meeting, karolinska institutet, stockholm. Channels (Austin) 2010;4:124-35
93. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of parkinson's disease. Nature 2007;447:1081-6
94. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of parkinson disease. Neurology 2008;70:1438-44
95. Roda JM, Carceller F, Diez-Tejedor E, et al. Reduction of infarct size by intraarterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 1995;26:1888-92
96. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005;36:619-24
97. Pantoni L, Bianchi C, Beneke M, et al. The scandinavian multi-infarct dementia trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000;175:116-23
98. Parnetti L, Senin U, Carosi M, et al. Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The nimodipine study group. Clin Ther 1993;15:394-406
99. Kaltenbach LS, Romero E, Becklin RR, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007;3:e82
100. Croisile B, Trillet M, Fondarai J, et al. Long-term and high-dose piracetam treatment of alzheimer's disease. Neurology 1993;43:301-5
101. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and alzheimer's disease. Epilepsy Behav 2010;17:461-6
102. Consejo Superior de Investigaciones Científicas. Compuestos. marinos antagonistas de los canales de calcio para el tratamiento de enfermedades cardiovasculares. ES2383858; 2012
103. Surmeier DJ. Selective calcium channel antagonists. US20120196883; 2012
104. Centro de Investigación y Desarrollo de Medicamentos. Tricyclic and tetracyclic systems with activity on the centralnervous and vascular systems. WO2011041989; 2011
105. Abbott Laboratories. Novel substituted octahydrocyclopenta[c]pyrrol-4- amines as calcium channel blockers. US20110281870; 2011
106. Convergence Pharmaceuticals Ltd. Piperazine derivatives as cav2.2 calcium channel blockers. WO2012098400; 2012
107. Convergence Pharmaceuticals Ltd. Tetrazole compounds as calcium channel blockers. WO2012004604; 2012
108. Abbvie, Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers. WO2013049164; 2013
109. Abbvie, Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers. WO2013049174; 2013
110. Indiana University Research and Technology Corporation. Materials and method for suppresing inflamatory and neuropathic pain. WO2012009075; 2012
111. Indiana University Research and Technology Corp. Peptide conjugates for treating pain. WO2013184614; 2013
112. Zalicus Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers. US8377968; 2013
113. Buset Rios N, Rodriguez Esparragon F, Fernandez-Andrade Rodriguez C, et al. Vascular and metabolic properties of manidipine. Nefrologia 2011;31:268-74
114. Mariot P, Vanoverberghe K, Lalevee N, et al. Overexpression of an alpha 1h (cav3.2) t-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 2002;277:10824-33
115. University of Virginia Patent Foundation. T type calcium channel blockers and the treatment of diseases. US20120264804; 2012
116. Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists. WO2011022315; 2011
117. Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists. WO2011053542; 2011
118. Merck Sharp & Dohme Corp. Imidazolyl methyl piperidine t-type calcium channel antagonists. WO2013148640; 2013
119. Concert Pharmaceuticals, Inc. Tetrahydronaphthalene derivatives as t-type calcium channel blocker. WO2013036434; 2013
120. Zenyaku Kogyo Kabushikikaisha. Use of cav3.1 selective t-type calcium channel antagonists. WO2012094615; 2012
121. Moriguchi S, Shioda N, Yamamoto Y, et al. The t-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer st101: enhancement of long-term potentiation and camkii autophosphorylation in rat cortical slices. J Neurochem 2012;121:44-53
122. Anderson D, Rehak R, Hameed S, et al. Regulation of the kv4.2 complex by cav3.1 calcium channels. Channels (Austin) 2010;4:163-7
123. Universite de Nice Sophia Antipolis. Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes. US20120040909; 2012
124. Abbott Laboratories. Lactam acetamides as calcium channel blockers. US20110230459; 2011
125. Hilpert K. Bridged tetrahydronaphthalene derivatives. US20110263648; 2011
126. Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers. US8273749; 2012
127. Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers. WO2012061926; 2012
128. Convergence Pharmaceuticals Ltd. Piperazine derivatives for blocking cav2.2 calcium channels. WO2011086377; 2011
129. Sevilla P, Bruix M, Santoro J, et al. Three-dimensional structure of omegaconotoxin gvia determined by 1h nmr. Biochem Biophys Res Commun 1993;192:1238-44
130. Kohno T, Kim JI, Kobayashi K, et al. Three-dimensional structure in solution of the calcium channel blocker omegaconotoxin mviia. Biochemistry 1995;34:10256-65
131. Nemoto N, Kubo S, Yoshida T, et al. Solution structure of omega-conotoxin mviic determined by nmr. Biochem Biophys Res Commun 1995;207:695-700
132. Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of omegaconotoxins at n-type voltage-sensitive calcium channels. J Mol Recognit 2000;13:55-70
133. Scott VE, Vortherms TA, Niforatos W, et al. A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dosedependent antinociception without altering hemodynamic function in rats. Biochem Pharmacol 2012;83:406-18
134. Yamamoto T, Takahara A. Recent updates of n-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 2009;9:377-95
135. Beedle AM, Zamponi GW. Block of voltage-dependent calcium channels by aliphatic monoamines. Biophys J 2000;79:260-70
136. Schmidtko A, Lotsch J, Freynhagen R, et al. Ziconotide for treatment of severe chronic pain. Lancet 2010;375:1569-77
137. Craik DJ, Adams DJ. Chemical modification of conotoxins to improve stability and activity. ACS Chem Biol 2007;2:457-68
138. Baell JB, Duggan PJ, Forsyth SA, et al. Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin gvia. Bioorg Med Chem 2004;12:4025-37
139. Menzler S, Bikker JA, Suman-Chauhan N, et al. Design and biological evaluation of non-peptide analogues of omega-conotoxin mviia. Bioorg Med Chem Lett 2000;10:345-7
140. Hu LY, Ryder TR, Rafferty MF, et al. The discovery of [1-(4-dimethylaminobenzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phen yl]-(3-methyl-but-2-enyl)-amine, an n-type ca+2 channel blocker with oral activity for analgesia. Bioorg Med Chem 2000;8:1203-12
141. Jun K, Piedras-Renteria ES, Smith SM, et al. Ablation of p/q-type ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1a)-subunit. Proc Natl Acad Sci USA 1999;96:15245-50
142. Fletcher CF, Tottene A, Lennon VA, et al. Dystonia and cerebellar atrophy in cacna1a null mice lacking p/q calcium channel activity. FASEB J 2001;15:1288-90
143. Bourinet E, Soong TW, Sutton K, et al. Splicing of alpha 1a subunit gene generates phenotypic variants of p-and q-type calcium channels. Nat Neurosci 1999;2:407-15
144. Soong TW, DeMaria CD, Alvania RS, et al. Systematic identification of splice variants in human p/q-type channel alpha1(2.1) subunits: implications for current density and ca2+-dependent inactivation. J Neurosci 2002;22:10142-52
145. Mezler M, Hermann D, Swensen AM, et al. Development and validation of a fluorescence-based hts assay for the identification of p/q-type calcium channel blockers. Comb Chem High Throughput Screen 2012;15:372-85
146. Nimmrich V, Gross G. P/q-type calcium channel modulators. Br J Pharmacol 2012;167:741-59
147. Armstrong GA, Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of tdp-43 mutation in als. J Neurosci 2013;33:1741-52
148. Voltage-gated calcium channels. IUPHAR/BPS Guide to PHARMACOLOGY. Available from: http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward? familyId=80 [Accessed on 15 June 2014]